Effects of Sitagliptin as Monotherapy and Add-On to Metformin on Weight Loss among Overweight and Obese Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Authors
Leila Janani1, Hadi Bamehr2, Kiarash Tanha1, Parastoo Mirzabeigi3, Hamed Montazeri4, Parastoo Tarighi5

Affiliations
1 Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran
2 Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
3 Department of Clinical Pharmacy, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran
4 Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Iran University of Medical Sciences, Tehran, Iran
5 Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran

Key words
Systematic review, Meta-analysis, Randomised clinical trial, Type 2 diabetes, Sitagliptin, Overweight, Metformin

ABSTRACT
Background Sitagliptin is known as an antidiabetic agent inhibiting the dipeptidyl peptidase-4. Although sitagliptin may influence weight, controversial results have been reported, and there is no general agreement on this issue. Therefore, this study assessed the effect of sitagliptin as monotherapy and add-on therapy to metformin on weight reduction in overweight or obese cases with type 2 diabetes.

Methods We reviewed the following databases to identify all relevant papers published until 1st April 2021: Web of Science, MEDLINE, Embase, Scopus, Cochrane Central Register of Controlled Trials Cochrane Library, and Google Scholar. The research included all clinical trials investigating the effect of sitagliptin in obese or overweight adult patients with type 2 diabetes without any language restriction.

Results In total, eighteen randomized controlled trials with 2009 participants were included in our meta-analysis. Results showed supplementation of sitagliptin has led to weight loss for sitagliptin treated (MD −0.99; 95 % CI; (−1.87, −0.12); p = 0.026)) and sitagliptin + metformin treated groups (MD −1.09; 95 % CI; (−1.69, −0.49); p < 0.001)). Also, the intervention has influenced body mass index in sitagliptin treated (MD −0.23; 95 % CI; (−0.45, 0.02); p = 0.033)) and sitagliptin + metformin treated groups (MD −0.52; 95 % CI; (−0.96, 0.08); p = 0.020) comparing to placebo.

Conclusion Our results demonstrated that sitagliptin administration with or without metformin might reduce the body weight and body mass index if these drugs are taken for more than 6 months.
Introduction

World Health Organization (WHO) explains obesity as an abnormal fat accumulation or excess body adiposity and a relapsing disease [1]. Obesity and overweight issues have attracted global attention due to their increasing prevalence, estimated at 38% of the world population in 2038 [2]. In recent years, obesity has increased primarily due to urbanization, reduced physical activity, and increased availability of food supplies [3]. Furthermore, the economic effect of obesity leads to the simultaneous expansion of social, medical, and public health costs [4]. There is a significant association between obesity and many chronic diseases, particularly type 2 diabetes [5]. Obesity or weight gain is associated with an increased risk of type 2 diabetes. Besides, obesity is a risk factor strongly related to the increased risk of cardiovascular disease [6, 7], responsible for around 70 to 80% of type 2 diabetes-related mortality [8, 9].

It is well established that weight reduction is associated with a low risk of developing type 2 diabetes [10, 11]. The weight loss issue has received considerable critical attention in managing type 2 diabetes, but weight loss strategies suffer from limited success [12]. Weight loss leads to improved glycemic control and a decreased need for glucose-lowering drugs in patients with diabetes. In overweight or obese type 2 diabetic adults, dietary recommendations, physical activity, and behavioral therapy are strongly considered to achieve weight loss. Based on the strong evidence, obesity management has a valuable role in slowing the progression of diabetes. In this regard, choosing the antidiabetic medications associated with weight loss in type 2 diabetic patients who have overweight or obese can be beneficial [13]. So far, a great deal of attention has been paid to the pharmacological approach. Antidiabetic agents such as insulin, sulfonylureas, and thiazolidinediones cause weight gain as their side-effects [14, 15].

Sitagliptin has been shown to preserve β-cell function and improve glycated hemoglobin (HbA1c), 2-h postprandial glucose.
Table 1  Characteristics of included studies.

<table>
<thead>
<tr>
<th>Authors (Year)</th>
<th>sample size</th>
<th>treatment duration (week)</th>
<th>Age * (year)</th>
<th>Intervention</th>
<th>BMI * (Kg/m²)</th>
<th>Weight * (kg)</th>
<th>Design study</th>
<th>Study location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaboe et. al. (2010)</td>
<td>41</td>
<td>12</td>
<td>59.5 (39–64)</td>
<td>SIT + MET</td>
<td>33.2 (29.3–39.4)</td>
<td>102 (89–127)</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>Denmark</td>
</tr>
<tr>
<td>Ozen Oz Gul et. al. (2011)</td>
<td>44</td>
<td>12</td>
<td>56.5 ± 8.8</td>
<td>SIT</td>
<td>31.6 ± 5.8</td>
<td>84.1 ± 17.0</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>Turkey</td>
</tr>
<tr>
<td>Derosa et. al. (2012)</td>
<td>178</td>
<td>12</td>
<td>55.9 ± 8.8</td>
<td>SIT + MET</td>
<td>28.9 ± 2.0</td>
<td>78.4 ± 6.6</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>Italy</td>
</tr>
<tr>
<td>Satish K. Garg et. al. (2013)</td>
<td>125</td>
<td>20</td>
<td>39 ± 15</td>
<td>SIT</td>
<td>27.5 ± 4.9</td>
<td>82 ± 16</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>Colorado</td>
</tr>
<tr>
<td>Bhosle et. al. (2017)</td>
<td>40</td>
<td>12</td>
<td>45.25 ± 7.22</td>
<td>SIT + MET</td>
<td>28.19 ± 0.91</td>
<td>75.40 ± 7.08</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>India</td>
</tr>
<tr>
<td>Ferjan et. al. (2017)</td>
<td>24</td>
<td>12</td>
<td>34.3 ± 6.8</td>
<td>SIT + MET</td>
<td>34.8 ± 5.4</td>
<td>100.4 ± 12.9</td>
<td>Prospective, open-label, randomized, controlled, parallel group clinical study</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Gadde et. al. (2017)</td>
<td>183</td>
<td>28</td>
<td>54.3 ± 9.0</td>
<td>SIT</td>
<td>31.6 ± 5.8</td>
<td>88.1 ± 20.3</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>Louisiana</td>
</tr>
<tr>
<td>Jinhua Yan et. al. (2017)</td>
<td>21</td>
<td>26</td>
<td>45.7 ± 9.2</td>
<td>SIT + MET</td>
<td>29.7 ± 2.8</td>
<td>82 ± 13.6</td>
<td>randomized, active-controlled, parallel-study design</td>
<td>China</td>
</tr>
<tr>
<td>Rosenstock et. al. (2019)</td>
<td>467</td>
<td>78</td>
<td>58 ± 10.0</td>
<td>SIT + MET</td>
<td>32.5 ± 6.2</td>
<td>90.9 ± 21.0</td>
<td>Randomized, double-blind, double-dummy, parallel-group</td>
<td>England</td>
</tr>
<tr>
<td>Ajmani et. al. (2019)</td>
<td>75</td>
<td>12</td>
<td>51.4 ± 8.79</td>
<td>SIT + MET</td>
<td>27 ± 4.42</td>
<td>69.2 ± 13.14</td>
<td>randomized, active-controlled, parallel-study design</td>
<td>India</td>
</tr>
<tr>
<td>Halvorsen et. al. (2019)</td>
<td>171</td>
<td>24</td>
<td>59.6 ± 9.8</td>
<td>SIT + MET</td>
<td>31.4 ± 5.3</td>
<td>Not reported</td>
<td>randomized, active-controlled, parallel-study design</td>
<td>USA</td>
</tr>
<tr>
<td>Hussain et. al. (2019)</td>
<td>50</td>
<td>12</td>
<td>54 ± 8</td>
<td>SIT</td>
<td>27 ± 4</td>
<td>Not reported</td>
<td>randomized, active-controlled, parallel-study design</td>
<td>Pakistan</td>
</tr>
<tr>
<td>Webb et. al. (2020)</td>
<td>33</td>
<td>26</td>
<td>44.8 ± 5.9</td>
<td>SIT</td>
<td>34.9 ± 5.3</td>
<td>100.7 ± 21.1</td>
<td>randomized, open label, active comparator trial</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Fuchigami et. al. (2020)</td>
<td>163</td>
<td>24</td>
<td>57.9 ± 12.1</td>
<td>SIT</td>
<td>27.9 ± 4.2</td>
<td>74.9 ± 15.0</td>
<td>prospective, randomized, open-label, blinded-endpoint, parallel-group trial</td>
<td>Japan</td>
</tr>
<tr>
<td>Hiruma et. al. (2020)</td>
<td>23</td>
<td>12</td>
<td>47.8 ± 11.5</td>
<td>SIT</td>
<td>30.0 ± 5.0</td>
<td>84.4 ± 16.1</td>
<td>prospective, randomized, open-label, blinded-endpoint, parallel-group trial</td>
<td>Japan</td>
</tr>
<tr>
<td>Kitazawa et. al. (2021)</td>
<td>48</td>
<td>52</td>
<td>58.4 ± 12.5</td>
<td>SIT + MET</td>
<td>26.8 ± 4.5</td>
<td>72.0 ± 15.6</td>
<td>randomized open-label trial</td>
<td>Japan</td>
</tr>
<tr>
<td>Smits et. al. (2021)</td>
<td>33</td>
<td>12</td>
<td>62.8 ± 6.9</td>
<td>SIT</td>
<td>31.5 ± 1.0</td>
<td>99.4 ± 3.8</td>
<td>Randomized, double-blind, placebo-controlled, parallel group clinical study</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Linong Ji et. al. (2021)</td>
<td>290</td>
<td>30</td>
<td>53.1 ± 10.4</td>
<td>SIT</td>
<td>27.3 ± 4.7</td>
<td>75.5 ± 14.7</td>
<td>Randomized, double-blind, double-dummy, parallel-group</td>
<td>China</td>
</tr>
</tbody>
</table>

* Data presented as “mean ± SD” or “median (range)” SIT: sitagliptin, MET: metformin, PBO: placebo.
(PPG), fasting plasma glucose (FPG), and hyperglycemia in individuals with type 2 diabetes [16, 17]. As the first oral dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin or gliptin was approved by the United States Food and Drug Administration (FDA) in 2006. It inhibits the DPP-4 receptor [18]. DPP-4 stimulates glucagon release and decreases insulin secretion by inactivating incretin such as glucagon-like peptide-1 (GLP-1) [19]. A severe reduction or loss of the incretin effect has also been reported in patients with type 2 diabetes [20]. GLP-1 is an essential incretin hormone promoting proliferation/neogenesis ratio and inhibiting beta cells’ apoptosis [21]. GLP-1 delays nutrient delivery by delaying gastric emptying, reducing postprandial glucose excursions [22], and might reinforce the change in eating behavior [23]. Accordingly, it is assumed that the enhancement of endogenous incretin induces weight loss through the inhibition of DPP-4. More recently, sitagliptin has been used as a treatment option for metformin failure in diabetes, polycystic ovary syndrome (PCOS), and as a preventive agent against the progression of type 2 diabetes and its comorbidities [24, 25]. Tran et al. conducted a meta-analysis about the efficacy of DPP-4 inhibitor compared to GLP-1 in managing type 2 diabetes. They concluded that GLP-1 performs better in weight loss and does not influence sitagliptin [26]. Juan’s meta-analysis about DDP-4 inhibitors failed to address the efficacy of sitagliptin on weight loss [27]. There are also discrepancies and sometimes controversies between clinical studies investigating the effect of sitagliptin on weight loss [28–32]. Thus, the present systematic review and meta-analysis are designed to assess the impact of sitagliptin on weight loss in type 2 diabetic obese or overweight adults.
Fig. 3  Point estimation of mean differences with 95% CI for body weight in single drug groups for before-after intervention. Forest plot for before-after comparison of body weight means in people who received sitagliptin as a monotherapy using random-effect-model meta-analysis. (ES; effect size, Weight: study weight in meta-analysis).

Fig. 4  Point estimation of mean differences with 95% CI for body weight in multiple drug groups for before-after intervention. Forest plot for before-after comparison of body weight means in people who received sitagliptin + metformin using random-effect-model meta-analysis (ES; effect size, Weight: study weight in meta-analysis).
Material & Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline was used to report the review.

Literature Search

We searched the following databases to find related Clinical Trials published until 1st April 2021: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE [PubMed], Scopus, Embase, and Web of Science. In addition, we searched the databases of the International Standard Randomized Controlled Trial Number (ISRCTN) Registry and Meta-Register for references of Randomized Controlled Trials (RCTs) for ongoing relevant publications. The search syntax was contained related keywords as follow: ((Weight or Obesity or BMI or “Body Mass” or Quetelet * ) and (Sitagliptin * ) and (Placebo or “Placebo Therapy” or “Placebo Control” or “Placebo Group”) and (Randomized Controlled Trials or “Randomized Controlled Trial” or “RCT” or “Controlled Clinical Trials”)).
or Januvia or Antiobesity or (MK and 0431) or (Prader - Willi and Syndrome)). We restricted the search to the studies conducted on humans. However, the research also included the literature published in any language. Additionally, after finalizing the search strategy and defining the inclusion criteria, an expletive search was conducted by searching through related articles’ references.

Inclusion and Exclusion Criteria

Eligible RCTs written in any language were only included in the analysis if they met the following framework: monotherapy with sitagliptin, combined treatment of sitagliptin with metformin, treatment duration of at least two months, providing weight and/or body mass index (BMI) values and the criteria for selecting the subjects were as follows: All the participants who were aged 18 years old and older at the beginning of the study with a medical history of type 2 diabetes and were classified as overweight or obese based on accepted standards such as BMI and body weight. Also, English abstracts of non-English papers were assessed if possible. In multiple publications of a study, the latest version with the most enrolled participants has been included. Studies written in other languages were translated sufficiently in detail if required.

Study Selection and Eligible Papers

Selected titles and abstracts were scanned by two reviewers independently (HB, KT) to identify eligible studies for further assessment. First, the abstracts were screened to remove irrelevant studies that did not meet inclusion criteria. Then, the inspection continued by reviewing the full text of all potentially relevant studies undertaken by two reviewers independently (HB, KT). Finally, according to the criteria, the study’s final stage was performed to reach an agreement and select the final papers. Controversies were resolved by consulting with a third person (LJ).

We assessed the bias risk of included studies using the Cochrane tool for assessing the risk of bias for randomized trials (RoB 2 tool), which is a domain-based critical assessment of the following issues: randomization process; intended intervention, missing outcome data, measurement of the outcome, reported results; which answers lead to judgments of “low risk of bias,” “some concerns,” or “high risk of bias” [33]. First, the differences between results were surveyed, and then they were resolved through discussion.

Data Extraction

Two reviewers (Hadi Bamehr, Kiarash Tanha) separately extracted the data from all included studies. The disagreement between the reviewers was resolved by a discussion with the third author (LJ). Eligible studies were reviewed, and the following data were collected: first authors’ name, publication year, study location, publication type, study design, number of the participants in the intervention and control groups, duration of the intervention, characteristics of the patients, age, sex, paramount inclusion and exclusion criteria, and outcomes including BMI, weight measures at baseline and end of each study.

Statistical analysis

Stata software version 13 (Stata Corp., College Station, TX, USA) was used for data analysis. Since all study outcomes ranged on a continuous scale, pooled estimates were reported as Mean Difference (MD) and 95% Confidence Interval (CI). MDs were calculated for before-after comparison in the intervention group and for comparing weight and BMI in intervention groups compared to placebo at the end of the study. Due to a lack of relevant data, we could not compare changes from baseline in control and intervention groups. Heterogeneity assessment between the studies was performed using the I2 statistic (the I2 values of 25, 50, and 75% indicated low, moderate, and high heterogeneities, respectively), representing the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error [34]. Cochran’s Q statistic was also used to determine the statistical significance of
Review

A total of 10924 potential citations were identified in our initial search. After the screening of titles and abstracts, 603 potentially eligible studies were retrieved for further analysis, among which, 579 RCTs were excluded from further analysis according to reviewing the full text of the studies because they were out of the borderline of expected outcomes. Finally, 18 RCTs entered to meta-analysis.

▶ Fig. 1 shows a detailed explanation regarding the processes of study selection step by step. ▶ Table 1 presents the key characteristics of the RCTs. The eighteen selected studies enrolled 2009 people, and the results indicated that sitagliptin was effective in reducing BMI and Body Weight.

Results

A meta-analysis was performed to determine whether the association differed depending on the type of treatment (single drug or multiple drugs) and supplementation duration (six months or less and more than six months). The publication bias was also evaluated in more than three studies using Egger's test for asymmetry of the funnel plots. The results showed that the association was statistically significant for all the tests except publication bias tests.

▶ Fig. 8 shows the point estimation of mean differences with 95% CI for BMI in single drug groups for comparison of sitagliptin group vs. placebo. Forest plot using fixed-effect model meta-analysis for comparison of BMI means in people who received sitagliptin as monotherapy vs. people who received placebo group (ES: effect size, Weight: study weight in meta-analysis).

▶ Fig. 9 shows the point estimation of mean differences with 95% CI for BMI in multiple drug groups for comparison of before-after intervention. Forest plot for before-after comparison of BMI means in people who received sitagliptin + metformin using random-effect model meta-analysis (ES: effect size, Weight: study weight in meta-analysis).
participants. All the included studies had been published after 2010. The participants in these trials were aged between 18 to 70 years old. Among all included studies, ten trials reported changes in BMI and weight [28, 29, 35–42], two studies only reported BMI [43, 44], and six studies only reported body weight [45–50].

**Effect of Sitagliptin on Body Weight**

Generally, seven selected RCTs reported the effects of supplementation of sitagliptin on body weight. Meta-analysis of the data indicated that, supplementation of sitagliptin has not led to body weight reduction in single-drug group for 6 months or less (MD = −0.54; 95% CI; (−1.11, 0.04); p = 0.066)), but the results showed it had significant effect for more than 6 months (MD = −1.68; 95% CI; (−3.19, −0.16); p = 0.016)) as shown in ▶ Fig. 4.

Also, results of comparison between intervention and control groups revealed that, treatment with sitagliptin as monotherapy had not a significant effect on reduction of body weight during 6 months or less (MD = 2.70; 95% CI; (−4.03, 9.43]; p = 0.431)) and more than 6 months (MD = −1.60; 95% CI; (−8.17, 4.97); p = 0.633)) in single -drug group as shown in ▶ Fig. 5 and (MD = −0.40; 95% CI; (−1.94, 1.14); p = 0.610)) during 6 months or less and (MD = −0.58; 95% CI; (−0.83, 1.98); p = 0.422)) for more than 6 months as multiple -drug group, respectively (∴ Fig. 6).

**Effect of Sitagliptin on BMI**

Although the supplementation of sitagliptin had not influenced BMI through separate subgroups of time (P-value > 0.05), the results of the meta-analysis showed a significant difference in overall time points (MD = −0.23; 95% CI; (−0.45, −0.02]; p = 0.033)) in the monotherapy group (∴ Fig. 7). Besides, the sitagliptin as an add-on to metformin has not influenced the BMI in multiple -drug group

#### Table 2  Subgroup analysis of the effects of sitagliptin supplementation as monotherapy and add on to metformin (‘single drug’ means sitagliptin, and ‘multidrug’ mean sitagliptin + metformin).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Intervention type</th>
<th>NO.</th>
<th>Subgroups</th>
<th>Pooled effect estimate</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight (Kg)</td>
<td>Intervention group (after vs. before)</td>
<td>5</td>
<td>Single-drug</td>
<td>−0.99</td>
<td>(−1.87, −0.12)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td>Multidrug</td>
<td>−1.09</td>
<td>(−1.69, −0.49)</td>
</tr>
<tr>
<td></td>
<td>Change intervention group vs. placebo group</td>
<td>3</td>
<td>Single-drug</td>
<td>0.959</td>
<td>(−3.98, 5.317)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7</td>
<td>Multidrug</td>
<td>0.13</td>
<td>(−0.90, 1.17)</td>
</tr>
<tr>
<td>BMI</td>
<td>Intervention group (after vs. before)</td>
<td>4</td>
<td>Single-drug</td>
<td>−0.23</td>
<td>(−0.45, −0.02)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>Multidrug</td>
<td>−0.520</td>
<td>(−0.96, −0.08)</td>
</tr>
<tr>
<td></td>
<td>Change intervention group vs. the placebo group</td>
<td>1</td>
<td>Single-drug</td>
<td>−0.533</td>
<td>(−1.281, 0.216)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>Multidrug</td>
<td>−0.52</td>
<td>(−1.199, 0.16)</td>
</tr>
</tbody>
</table>
during 6 months (MD $-0.15$; 95% CI: $(-0.53, 0.24); p = 0.462)) but showed a significant effect in more than 6 months, (MD $-0.88$; 95% CI: $(-1.34, -0.42); p < 0.001)) (▶ Fig. 8).

Additionally, the effect of sitagliptin administration on BMI and Weight was analyzed between intervention and control groups. A significant reduction has not been shown in the pooled MDs for sitagliptin as monotherapy or with metformin compared to placebo. Mean differences of intervention-control comparison were (MD $-0.53$; 95% CI: $(-1.28, 0.22); p = 0.163)) and (MD $-0.52$; 95% CI: $(-1.20, 0.62); p = 0.134)) respectively,. as depicted in detail in ▶ Fig. 9 and ▶ Fig. 10.

Table 2 illustrates the effects of the intake of sitagliptin on body weight and BMI based on subgroup analysis. Findings of stratified analyses revealed that the effects were different due to the type of intervention.

Publication Bias Assessment

Evidence of publication bias was visually detected using funnel plot asymmetry and quantified by Egger's test ($P < 0.10$). Visual inspection of the funnel plot represented no asymmetry, and there were no small-study effects or publication biases as assessed by Egger's test (▶ Fig. 11a-d).

Risk of Bias Assessment for RCTs

The quality evaluation of the included studies was based on Cochrane Handbook for Systematic Reviews of Interventions, and ▶ Fig. 2a, b present the results obtained from the risk of bias assessment.

Discussion

Considerable attention has been devoted to weight loss in recent years. It has been well established that obesity is associated with an increased risk of developing diabetes and other complications such as insulin resistance and cardiovascular diseases [51–54]. Previous studies acknowledged the critical role of obesity, and it has been reported that more than two-thirds of the individuals who have type 2 diabetes are overweight or obese [55]. It is well known that weight loss leads to significant improvements in insulin secretion, sensitivity, reduction in cardiovascular risk, and better outcomes for patients with type 2 diabetes [56]. Therefore, weight loss is a significant area of interest during the treatment of obese subjects through glycemic control. DPP-4 inhibitors are known as a novel class of glucose-lowering agents, which have been reported to reduce blood glucose levels by inhibiting DPP-4 [57] and improving pancreatic β-cell function in type 2 diabetes. The
sitagliptin is classified as one of the first DPP-4 inhibitors approved by the FDA for clinical use in 2006 [58]. Now, two inhibitors include vildagliptin and sitagliptin, are available on the market for oral administration. The sitagliptin can be used in combination with other antidiabetic drugs such as metformin, sulfonylurea, or thiazolidinedione compounds for individuals with inadequate glycemic control after treatment with traditional antidiabetic medications.

Though substantial research has been conducted on the influence of DPP-4 inhibitors on reducing weight and BMI, there are somewhat controversial experimental data about the effect of sitagliptin. There is no general agreement on the fact that sitagliptin has the potential to reduce weight [59].

Previous studies only focused on all three DPP-4 inhibitors, and they have been reported not to affect weight [60, 61]. In this regard, no comprehensive systematic review has been conducted to determine the effect of sitagliptin on body weight. So, we can say that a meta-analysis of RCTs provides a comprehensive assessment to gain a detailed understanding of the impact of sitagliptin on weight loss. However, further prospective studies are needed to investigate the weight loss effect of this drug to develop a complete picture regarding the usage of sitagliptin.

The lack of enough information on available trials was a limitation in the present study. For instance, in several trials, the sitagliptin's evaluation of the weight loss effect had not been reported as a preferred outcome at the end of the treatment. Despite the use of random effect models and subgroup analysis, which mainly led to the reduction of I² statistic of heterogeneity, lack of large sample studies, and presence of heterogeneous studies is one of the considerable limitations of this study.

Conclusions

This review identified that administration of sitagliptin solely and in combination with metformin for more than 6 months has improved body weight and body mass index reduction.

Further research studies are required to explore this association. This may subsequently help to improve interventions for weight management of people with type 2 diabetes.

Acknowledgments

This study was supported by grant No. 12978 from Iran University of Medical Sciences.

Competing Interests

The authors declare that they have no competing interests.

References

[41] Kitazawa M, Katagiri T, Suzuki H et al. A 52-week randomized controlled trial of iragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study, Diabetes, Obesity and Metabolism 2021; 23: 811–821